United States
Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity
Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost
Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country
Roche (company), Indiana, United States, Investments, expansion, Pennsylvania, Expanding, upgrade, Research Organization
UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU
EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price
U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs
U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.
Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.
Novartis to invest $23B in manufacturing so ‘all key medicines’ can be made in the US
Novartis, United States, Investments, Manufacture, production, Biological Factors, Novartis
Global Pharmaceutical Stocks Plummet Amid Trump’s Imminent Tariff Threats
Pharmaceutical tariffs, global pharma stocks, Trump import tariffs, drug manufacturing, supply chain disruption, pharmaceutical trade war, U.S. pharma policy
Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling
NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.
Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing
Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks